Loss-of-function mutations of the TIE1 receptor tyrosine kinase cause late-onset primary lymphedema.

Genetic diseases Genetics Lymph Mouse models Vascular biology

Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
30 May 2024
Historique:
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 31 5 2024
Statut: aheadofprint

Résumé

Primary lymphedema (PL), characterized by tissue swelling, fat accumulation and fibrosis, results from defective lymphatic vessels or valves caused by mutations in genes involved in development, maturation and function of the lymphatic vascular system. Pathogenic variants in various genes have been identified in about 30% of PL cases. By screening of a cohort of 755 individuals with PL, we identified two TIE1 (tyrosine kinase with immunoglobulin- and epidermal growth factor-like domains 1) missense variants and one truncating variant, all predicted to be pathogenic by bioinformatic algorithms. The TIE1 receptor, in complex with TIE2, binds angiopoietins to regulate the formation and remodelling of blood and lymphatic vessels. The premature stop codon mutant encoded an inactive truncated extracellular TIE1 fragment with decreased mRNA stability and the amino acid substitutions led to decreased TIE1 signaling activity. By reproducing the two missense variants in mouse Tie1 via CRISPR-Cas9, we showed that both cause edema and are lethal in homozygous mice. Thus, our results indicate that TIE1 loss-of-function variants can cause lymphatic dysfunction in patients. Together with our earlier demonstration that ANGPT2 loss-of-function mutations can also cause PL, our results emphasize the important role of the ANGPT2-TIE1 pathway in lymphatic function.

Identifiants

pubmed: 38820174
pii: 173586
doi: 10.1172/JCI173586
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Pascal Brouillard (P)

Laboratory of Human Molecular Genetics, University of Louvain, Brussels, Belgium.

Aino Murtomäki (A)

Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland.

Veli-Matti Leppänen (VM)

Translational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.

Marko Hyytiäinen (M)

Translational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.

Sandrine Mestre (S)

Department of Vascular Medicine, CHU Montpellier, Université de Montpellier, Montpellier, France.

Lucas Potier (L)

Laboratory of Human Molecular Genetics, University of Louvain, Brussels, Belgium.

Laurence M Boon (LM)

Division of Plastic Surgery, Université catholique de louvain and Clinique universitaire St-Luc, Brussels, Belgium.

Nicole Revencu (N)

Centre for Human Genetics, Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium.

Arin K Greene (AK)

Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, United States of America.

Andrey Anisimov (A)

Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland.

Miia H Salo (MH)

Research Unit of Clinical Medicine and Medical Research Center Oulu, University of Oulu, Oulu, Finland.

Reetta Hinttala (R)

Research Unit of Clinical Medicine and Medical Research Center Oulu, University of Oulu, Oulu, Finland.

Lauri Eklund (L)

Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland.

Isabelle Quéré (I)

Department of Vascular Medicine, CHU Montpellier, Université de Montpellier, Montpellier, France.

Kari Alitalo (K)

Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland.

Miikka Vikkula (M)

Laboratory of Human Molecular Genetics, University of Louvain, Brussels, Belgium.

Classifications MeSH